Status:
COMPLETED
The Role of Biomarkers and Echocardiography in Prediction of Prognosis of Chronic Heart Failure Patients
Lead Sponsor:
Erasmus Medical Center
Collaborating Sponsors:
Medical Center Alkmaar
Conditions:
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
The Bio-SHiFT study aims to investigate whether disease progression in individual patients with chronic heart failure (CHF) can be accurately assessed by serial measurements of disease-related (novel)...
Eligibility Criteria
Inclusion
- Men and women, aged 18 years or older, capable of understanding and signing informed consent
- Diagnosis of chronic heart failure (with diminished ejection fraction or with normal ejection fraction), according to the guidelines of the European Society of Cardiology (ESC)
Exclusion
- Heart failure secondary to circulatory high output conditions
- Scheduled for surgery or intervention for both coronary and non-coronary indication
- Severe renal failure for which dialysis is needed
- Known moderate or severe liver disease
- Chronic Obstructive Pulmonary Disease (COPD) Gold stage IV
- Congenital heart disease
- Coexistent condition with life expectancy ≤ 1 year
- Unlikely to appear at all scheduled follow-up visits
- Linguistic barrier
Key Trial Info
Start Date :
August 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2020
Estimated Enrollment :
398 Patients enrolled
Trial Details
Trial ID
NCT01851538
Start Date
August 1 2011
End Date
November 1 2020
Last Update
February 8 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Center Alkmaar
Alkmaar, Netherlands
2
Erasmus MC
Rotterdam, Netherlands